Skip to main content

Fiscal Wizard · Single-issue tearsheet

ORGO / Jun 20, 2026 Run #7265

ORGO

Organogenesis Holdings Inc.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Composite verdict

F 22.2 / 100
Bearish setup · Trend Following 10 drivers · 6 gates blocking
  • Accumulation/Distribution Line
  • Vortex Signal
  • Elder Force Index
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 47th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 49

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -61%
Asset value $2.33Earnings power value $3.25Price $2.44

The discount is mostly unpriced earnings power: price ($2.44) sits between asset value ($2.33) and no-growth earnings power value ($3.25).

Fundamentals Mixed

44.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Asset Turnover 86
OCF to Net Income 0
Greenblatt EY 84
Free Cash Flow Yield 0

Technicals Bearish

0.2 / 100

Bearish setup leads (Accumulation/Distribution Line, Vortex Signal, Elder Force Index); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 5
Vortex Signal 10
Elder Force Index 12

Risk Gates

6 blocking 4 caution

6 guards active, 25 signals gated.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ORGO.